In this New York Times op-ed, “The Republicans’ Jekyll-and-Hyde Health Care Plan,” Drew Altman examines the Senate health plan.
- view as grid
- view as list
In his Axios column, Drew Altman examines how the core views Republicans have about Medicaid differ from those of Democrats and Independents, and how those views drive the policy changes they are proposing for the program.
In this Axios column, Drew Altman highlights that the federal debate about the American Health Care Act’s Medicaid spending reductions will ultimately be a debate about every state’s general budget spending priorities, as states discuss whether to offset reductions in federal revenues with some combination of cuts to their Medicaid programs, increased taxes, and cuts to spending in other areas.
In this Axios column, Drew Altman lays out how the “political pain” from the American Health Care Act would play out over the next two election cycles if passed in its current form, based on the Congressional Budget Office’s analysis of the House-passed bill.
New England Journal of Medicine: Undermining Genetic Privacy? Employee Wellness Programs and the Law
In this May 2017 post, Karen Pollitz and co-author Kathy L. Hudson discuss how H.R. 1313, the Preserving Employee Wellness Programs Act, could substantially change current legal protections for the collection and treatment of genetic information and other personal health information under workplace wellness programs. The post is now available from the New England Journal of Medicine.
With Medicaid about to be a focal point of debate in the Senate, Drew Altman’s Axios column looks at why the idea that the program is broken is more urban legend than fact.
In this Axios column, Drew Altman analyzes new poll findings which show how one issue breaks through the gridlock between Democrats and Republicans in health – the high cost of prescription drugs.
In this column as an Axios contributor, Drew Altman discusses President Trump’s threat to withhold cost sharing subsidies and questions whether his approach to deal making can bridge health care’s partisan and ideological divide. “Health policy is not like real estate,” he says.
In this April 2017 post, Larry Levitt discusses the current status of the Affordable Care Act’s health insurance marketplaces, and explains how the Trump administration’s choices — including whether to continue cost-sharing reduction payments to insurers — could influence stability of the marketplaces going forward. The post is now available at The JAMA Forum.
In this column for Axios, Drew Altman sees a warning for the Trump administration and Republicans in the latest Kaiser Tracking Poll: the more they do to undermine the Affordable Care Act marketplaces the more the public is likely to hold them, and not the Democrats, accountable for the problems with the law.